Procept Biorobotics (PRCT) Q1 2026: U.S. System ASP Hits $485K, Pricing Discipline Drives Margin Recovery
Procept Biorobotics’ first quarter marked an inflection in pricing power, with U.S. system average selling prices reaching an all-time high and gross margins rebounding to target levels. The company’s commercial realignment is still settling, but early evidence shows operational and financial discipline taking hold, especially in capital equipment. Management is signaling sustained focus on profitability levers, with a measured outlook on procedure ramp and international expansion as key watchpoints for the remainder of 2026.
Summary
- Capital Discipline: U.S. system pricing surged to record highs as price discipline became central to strategy.
- Commercial Realignment Settling: Sales and clinical teams are adapting to new structures, with procedure growth expected to accelerate in H2.
- Margin Recovery Holds: Gross margin returned to 65%, with sequential improvement anticipated as pricing and mix stabilize.
Performance Analysis
Procept Biorobotics delivered 20% year-over-year revenue growth in Q1 2026, led by robust U.S. system sales and steady international momentum. U.S. revenue comprised the vast majority of the business, with system ASPs, or average selling prices, climbing to $485,000—a 14% sequential increase and the highest in company history. This jump was attributed to broad-based demand rather than concentration among large integrated delivery networks (IDNs), which often carry lower pricing due to volume discounts.
Handpiece sales, which are a recurring consumable revenue stream tied to procedure volume, tracked at 95% of procedures, reflecting normalized customer purchasing post-inventory adjustments. Gross margin rebounded sharply to 65%, up from 61% in Q4, driven by higher ASPs, improved product mix, and better overhead absorption. However, operating expenses rose significantly as the company invested in commercial expansion, R&D, and clinical trials, resulting in a wider net loss and continued negative adjusted EBITDA. Cash reserves remain strong at $249 million, supporting ongoing growth initiatives.
- System ASP Upside: Price discipline and broad-based demand drove U.S. system ASPs to record levels, signaling improved commercial leverage.
- Handpiece Normalization: Handpiece-to-procedure ratios stabilized, with management confident in achieving a full-year 1:1 ratio.
- Margin Expansion: Gross margin returned to target, with sequential improvement expected as pricing and product mix trends persist.
The first quarter set a new baseline for margin and pricing discipline, but the company must now prove it can translate these gains into accelerating procedure growth and eventual profitability as commercial changes settle.
Executive Commentary
"We have sharpened our focus on operational excellence, accountability, and commercial discipline. Our first quarter performance reflects the early impact of these efforts... establishing price discipline remains fundamental to long-term value creation."
Larry Wood, Chief Executive Officer
"Gross margin for the first quarter... was 65% compared to 64% in the first quarter of 2025 and 61% in the fourth quarter of 2025. The improvement was driven by increased pricing, cost discipline, and favorable product mix."
Kevin Waters, Chief Financial Officer
Strategic Positioning
1. Commercial Realignment and Launch Team Model
Procept Biorobotics restructured its commercial organization, integrating sales and clinical teams under regional leadership to drive accountability and coordinated execution. The dedicated launch team model is designed to accelerate new site activation and ramp procedure volumes, with management expecting the full benefit to materialize in the second half of 2026.
2. Pricing Power and Value Proposition
Establishing price discipline across both systems and handpieces has become a cornerstone of the company’s profitability strategy. The Q1 ASP surge was achieved without reliance on large, price-sensitive IDN deals, suggesting sustainable pricing strength. Management intends to maintain flexibility for customer mix but is committed to holding or modestly increasing ASPs through the year.
3. Margin Management and Profitability Path
Gross margin recovery to 65% aligns with full-year guidance, supported by higher ASPs and cost control. Management expects modest sequential margin expansion, targeting positive adjusted EBITDA in Q4. Tariff costs remain a headwind, but potential refunds could provide upside not currently in guidance.
4. International Expansion and Clinical Validation
International revenue remains a small but growing contributor, with the UK launch of HYDROS and strong clinical guideline endorsements supporting future growth. The company is prioritizing markets with favorable reimbursement and capital dynamics, aiming for gradual geographic diversification.
5. Clinical Pipeline and Adjacent Market Opportunities
Progress on the Water Forward prostate cancer trial and new AI-enabled planning capabilities position the company for potential expansion into adjacent indications and further differentiation of its robotic platform. Early completion of trial enrollment and strong clinical evidence underpin management’s confidence in long-term adoption.
Key Considerations
This quarter marks a transition from commercial restructuring to execution, with investors watching for evidence that operational discipline can translate to sustained growth and margin improvement. The interplay between pricing power, procedure ramp, and capital allocation will be pivotal in defining the company’s trajectory through 2026.
Key Considerations:
- Pricing Sustainability: The durability of elevated system ASPs as customer mix shifts and larger IDN deals re-enter the pipeline.
- Procedure Growth Acceleration: The pace at which procedure volumes rebound as the commercial realignment stabilizes and launch team model matures.
- Operating Expense Leverage: Ability to control opex growth while investing in commercial, R&D, and clinical initiatives.
- International Execution: Effectiveness in scaling UK and other targeted markets without diluting margin profile.
- Clinical Readouts and Adjacent Indications: Potential impact of Water Forward trial and AI software on market expansion and competitive positioning.
Risks
Execution risk remains elevated as commercial realignment is still in early innings, with procedure growth and utilization yet to reflect full benefits. Margin gains could be pressured if pricing discipline is challenged by customer mix or competitive dynamics, and operating losses persist as investments ramp. Regulatory and reimbursement changes, particularly in international markets, add further uncertainty.
Forward Outlook
For Q2 2026, Procept Biorobotics guided to:
- Total revenue of $91 to $95 million
- New U.S. system ASPs in the $450,000 to $460,000 range
For full-year 2026, management maintained guidance:
- Total revenue of $390 to $410 million
- Gross margin of approximately 65%
- Adjusted EBITDA loss of $30 to $17 million, with positive adjusted EBITDA in Q4
Management emphasized confidence in achieving full-year targets as commercial changes settle, with upside possible if pricing and procedure ramp trends hold. The company expects to update guidance post-Q2 as visibility improves.
- H2 procedure growth acceleration is expected as new launches and patient activation initiatives mature.
- International revenue to reach $50 to $51 million, with UK expansion as a key driver.
Takeaways
Procept Biorobotics is demonstrating early success in pricing discipline and margin recovery, but must now deliver on procedure growth and operating leverage as its commercial transformation takes hold.
- Pricing Power Is Real: U.S. system ASPs hit new highs, validating the company’s value proposition and setting a higher baseline for future capital sales.
- Commercial Realignment Needs Proof: The impact of launch teams and sales integration will be measured by H2 procedure acceleration and sustained utilization improvements.
- Profitability Path Under Scrutiny: Investors should watch for margin durability, opex control, and the ability to achieve positive adjusted EBITDA as planned by year-end.
Conclusion
Q1 2026 was a pivotal quarter for Procept Biorobotics, with strong pricing and margin performance offset by the ongoing transition in commercial execution. The company’s ability to sustain these gains and accelerate procedure growth will be the critical test for 2026.
Industry Read-Through
Procept’s ASP and margin rebound underscores a broader trend in medtech toward value-based pricing and operational discipline, especially for capital-intensive robotic platforms. Competitors should note the importance of commercial integration and launch team models in driving downstream utilization and maximizing system ROI. International expansion remains selective, with targeted markets and clinical evidence serving as primary growth catalysts. Clinical guideline endorsements and AI-driven workflow enhancements are becoming increasingly important differentiators in urology and adjacent procedural markets.